TARS
NASDAQTarsus Pharmaceuticals Inc.
Price$68.10-1.85 (-2.64%)
01:30 PM07:45 PM
News · 26 weeks73-67%
2026-04-192026-10-11
Mix3490d
- SEC Filings13(38%)
- Insider8(24%)
- Other7(21%)
- Earnings3(9%)
- Analyst2(6%)
- Offering1(3%)
Latest news
25 items- PRLisata Therapeutics Appoints Jeff Farrow to Board of DirectorsLIBERTY CORNER, N.J., Oct. 14, 2026 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (NASDAQ:LSTA) ("Lisata" or the "Company") today announced the appointment of Jeffrey Farrow to its Board of Directors, effective October 13, 2026. Mr. Farrow fills a newly created seat, expanding the Board from seven to eight members. He was appointed as a Class III director upon the recommendation of the Nominating and Corporate Governance Committee and will also serve on the Audit Committee. The Board has determined that Mr. Farrow is independent under Nasdaq listing rules. "Jeff has helped take multiple companies from the clinic to approval and commercial launch, and he has led several of them through su
- SECSEC Form S-3ASR filed by Tarsus Pharmaceuticals Inc.S-3ASR - Tarsus Pharmaceuticals, Inc. (0001819790) (Filer)
- SECSEC Form S-3ASR filed by Tarsus Pharmaceuticals Inc.S-3ASR - Tarsus Pharmaceuticals, Inc. (0001819790) (Filer)
- SECAmendment: SEC Form 8-K/A filed by Tarsus Pharmaceuticals Inc.8-K/A - Tarsus Pharmaceuticals, Inc. (0001819790) (Filer)
- PRTarsus Plans to Present 11 Abstracts Highlighting New Insights in Demodex Blepharitis, Ocular Rosacea and the Real-World Impact of XDEMVY at the American Academy of Optometry 2026 Annual MeetingIRVINE, Calif., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) today announced that it expects to present 11 scientific abstracts at the American Academy of Optometry (AAOpt) 2026 Annual Meeting, taking place Sept. 30–Oct. 3 in Anaheim, California. The planned abstracts provide new insights into the patient burden, diagnosis and treatment of Demodex blepharitis (DB); real-world experiences and outcomes with XDEMVY® (lotilaner ophthalmic solution) 0.25%; and the prevalence and clinical characteristics of ocular rosacea. Together, the findings are expected to add to a growing body of evidence intended to help eye care professionals better recognize and manage
- ANALYSTGoldman resumed coverage on Tarsus Pharmaceuticals with a new price targetGoldman resumed coverage of Tarsus Pharmaceuticals with a rating of Buy and set a new price target of $116.00
- INSIDERDirector Pyott David E I converted options into 201 shares (SEC Form 4)4 - Tarsus Pharmaceuticals, Inc. (0001819790) (Issuer)
- INSIDERDirector Link William J Phd converted options into 201 shares and sold $979,744 worth of shares (12,500 units at $78.38) as part of a pre-agreed trading plan, decreasing direct ownership by 12% to 94,487 units (SEC Form 4)4 - Tarsus Pharmaceuticals, Inc. (0001819790) (Issuer)
- INSIDERDirector Yarno Wendy L converted options into 302 shares, increasing direct ownership by 2% to 16,956 units (SEC Form 4)4 - Tarsus Pharmaceuticals, Inc. (0001819790) (Issuer)
- ANALYSTBarclays resumed coverage on Tarsus Pharmaceuticals with a new price targetBarclays resumed coverage of Tarsus Pharmaceuticals with a rating of Overweight and set a new price target of $110.00
- SECSEC Form 144 filed by Tarsus Pharmaceuticals Inc.144 - Tarsus Pharmaceuticals, Inc. (0001819790) (Subject)
- SECTarsus Pharmaceuticals Inc. filed SEC Form 8-K: Financial Statements and Exhibits8-K - Tarsus Pharmaceuticals, Inc. (0001819790) (Filer)
- INSIDERPresident/CEO and Board Chair Azamian Bobak R. sold $905,600 worth of shares (10,000 units at $90.56) as part of a pre-agreed trading plan (SEC Form 4)4 - Tarsus Pharmaceuticals, Inc. (0001819790) (Issuer)
- INSIDERChief Operating Officer Neervannan Seshadri sold $387,940 worth of shares (4,564 units at $85.00) as part of a pre-agreed trading plan, decreasing direct ownership by 5% to 78,532 units (SEC Form 4)4 - Tarsus Pharmaceuticals, Inc. (0001819790) (Issuer)
- INSIDERChief Medical Officer Lin Elizabeth Yeu sold $1,220,885 worth of shares (13,953 units at $87.50) as part of a pre-agreed trading plan, decreasing direct ownership by 81% to 2,547 units (SEC Form 4)4 - Tarsus Pharmaceuticals, Inc. (0001819790) (Issuer)
- PRTarsus Pharmaceuticals Completes Acquisition of Alkeus Pharmaceuticals, Expanding Leadership in Eye CareAdds gildeuretinol (ALK-001), a differentiated Phase 3 oral investigational medicine designed to target the underlying biology of Stargardt’s disease, a potentially blinding disease with no FDA-approved therapy Strengthens Tarsus’ differentiated pipeline and leadership in eye care IRVINE, Calif., Sept. 04, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) today announced that it has completed its previously announced acquisition of Alkeus Pharmaceuticals, Inc., a privately held retinal disease-focused biotechnology company. With the completion of the acquisition, Tarsus adds worldwide rights to ALK-001, a new, investigational, late-stage molecular entity designed to re
- INSIDERPresident/CEO and Board Chair Azamian Bobak R. sold $800,600 worth of shares (10,000 units at $80.06) as part of a pre-agreed trading plan (SEC Form 4)4 - Tarsus Pharmaceuticals, Inc. (0001819790) (Issuer)
- INSIDERChief Medical Officer Lin Elizabeth Yeu sold $897,990 worth of shares (11,578 units at $77.56) as part of a pre-agreed trading plan, decreasing direct ownership by 43% to 13,320 units (SEC Form 4)4 - Tarsus Pharmaceuticals, Inc. (0001819790) (Issuer)
- PRAlkeus Announces Publication in JAMA Ophthalmology of Efficacy and Safety Results from the TEASE-1 Study of Gildeuretinol in Stargardt DiseaseDaily treatment with oral gildeuretinol met the primary endpoint and resulted in a statistically significant reduction in the growth rate of retinal atrophic lesions compared to untreated group.Gildeuretinol was well tolerated with no patient-reported events of dark adaptation delays or night blindness.The publication provides the first peer-reviewed report of efficacy and safety results from a randomized, double-masked, placebo-controlled study in Stargardt disease. CAMBRIDGE, Mass., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Alkeus Pharmaceuticals, Inc., a biopharmaceutical company dedicated to preserving the sight of individuals impacted by retinal diseases, today announced the publication in
- SECSEC Form 144 filed by Tarsus Pharmaceuticals Inc.144 - Tarsus Pharmaceuticals, Inc. (0001819790) (Subject)
- PRTarsus to Participate in Upcoming Investor ConferencesIRVINE, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS), today announced that management plans to attend the following upcoming investor conferences: Wells Fargo 21st Annual Healthcare Conference on Tuesday, September 8thH.C. Wainwright 28th Annual Global Investment Conference on Tuesday, September 15th, where management plans to participate in a fireside chat at 6:00 a.m. PT / 9:00 a.m. ET. Live webcasts and additional information can be accessed on the events section of the Tarsus website. Replays will be available on the Tarsus website within 48 hours and will be archived for a limited time. About Tarsus Pharmaceuticals, Inc.Tarsus Pharmaceutical
- SECSEC Form 144 filed by Tarsus Pharmaceuticals Inc.144 - Tarsus Pharmaceuticals, Inc. (0001819790) (Subject)
- SECSEC Form 144 filed by Tarsus Pharmaceuticals Inc.144 - Tarsus Pharmaceuticals, Inc. (0001819790) (Subject)
- PRAlkeus Pharmaceuticals Announces Japan Ministry of Health, Labour and Welfare (MHLW) Has Granted Orphan Drug Designation to Gildeuretinol for Stargardt DiseaseCAMBRIDGE, Mass., Aug. 24, 2026 (GLOBE NEWSWIRE) -- Alkeus Pharmaceuticals, Inc., a biopharmaceutical company dedicated to preserving the sight of individuals impacted by retinal diseases, today announced that the Ministry of Health, Labour and Welfare (MHLW) in Japan has granted Orphan Drug Designation for oral gildeuretinol for the treatment of Stargardt disease. Stargardt disease is an inherited retinal disease that often begins in childhood or adolescence, and progressively and irreversibly damages the central vision patients rely on to read, recognize faces, drive and live independently. Gildeuretinol currently is being evaluated in the global Phase 3 NORTHSTAR Study. "Receiving orph
- SECSEC Form 144 filed by Tarsus Pharmaceuticals Inc.144 - Tarsus Pharmaceuticals, Inc. (0001819790) (Subject)
TARS FAQ
7 questionsWhat does Tarsus Pharmaceuticals Inc. do?
Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic that is in Phase IIb/III for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. The company is also developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in...Where does TARS stock trade?
Tarsus Pharmaceuticals Inc. (TARS) is listed on NASDAQ.What sector and industry is TARS in?
Tarsus Pharmaceuticals Inc. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.When did Tarsus Pharmaceuticals Inc. go public?
Tarsus Pharmaceuticals Inc. (TARS) completed its IPO in 2020.What are analysts saying about TARS?
Tarsus Pharmaceuticals Inc. has had 8 recent analyst actions on file. The most recent action was from Goldman: Buy on 2026-09-24. Recent price targets cluster around $1900.00.What companies are similar to TARS?
Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), MRNA (Moderna Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.). Compare TARS side-by-side with any of them on Quantisnow.How can I track TARS on Quantisnow?
Quantisnow aggregates Tarsus Pharmaceuticals Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow TARS to receive live email and push alerts on every new disclosure.